Not to be used to increase dose of cytotoxic chemotherapy. Risk of cross-reaction. Discontinue if WBC count is >50 x 10
9/L; preliminary signs of acute resp distress syndrome occurs. Not to be used in patients w/ chronic myeloid leukaemia, myelodysplastic syndromes or secondary AML. Patients w/ recent history of pulmonary infiltrates or pneumonia; capillary leak syndrome; sickle cell anaemia. Increased risk on hypokalaemia. Reversible thrombocytopenia; leukocytosis; splenomegaly & splenic rupture; aortitis, glomerulonephritis. Regularly monitor platelet count & haematocrit. Carefully monitor spleen size; serum K level; urine. Perform WBC count at regular intervals during therapy. Fructose intolerance. Concomitant use w/ single or combination chemotherapeutic medicinal products causing severe thrombocytopenia. Avoid use during pregnancy. Lactation. Childn & adolescents ≤17 yr.